Human epidermal growth factor receptor 2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis
=====================================================================================================================================================

Human epidermal growth factor receptor 2 (HER2) receptor, a member of the tyrosine kinase receptor family, has been widely studied as an important prognostic and predictive factor in breast cancer. Recently, a number of studies have implicated HER2 in a variety of other cancer types, including gastrointestinal malignancies. In their important work, Meng and coworkers carried out a retrospective analysis of a cohort of patients with locally advanced rectal carcinoma to examine the relationship between HER2 status and disease outcomes. The authors found that HER2 was associated with worse survival, including reduced 5-year overall survival. These findings support previous work that HER2 expression may be associated with a poorer prognosis and further support the use of HER2-directed therapies in locally advanced rectal cancer.
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Expression of CD24 is associated with human epidermal growth factor receptor 2 (HER2) expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
=====================================================================================================================================================================

Up to 20% of all invasive breast cancers express human epidermal growth factor receptor 2 (*HER2*) gene amplification, which is associated with a poorer prognosis but is susceptible to mAbs directed against the PI3K-Akt/MAPK pathways. Despite advances in therapy, relapse and resistance to medication rates are high. In this study, using *in vitro* breast cancer cells, the biochemical pathway that leads to this overexpression and subsequent resistance was investigated and found to be highly correlated with overexpression of CD24, a known negative prognostic factor in many cancers. Furthermore, it was elucidated that the knockdown of CD24 not only reduced the expression of HER2, but also served to suppress the PI3K-Akt pathway. This exciting work increases understanding of how HER2-positive breast cancer gains its aggressive behavior and offers a possible future target that might reduce the mortality rates associated with this deadly disease.
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Glabridin attenuates the migratory and invasive capacity of breast cancer cells by activating microRNA-200c
===========================================================================================================

Metastatic breast cancer has high rates of mortality worldwide. Although systemic therapies may delay progression, there are no clear ways to prevent the development of metastatic disease. Glabridin (GLA), a component of the licorice root, has been implicated in a number of antitumorigenic and antimetastatic processes. Ye and coworkers applied cell culture and molecular techniques to investigate the mechanism by which GLA may impair progression of breast malignancies. They found that GLA reduced the invasive and metastatic potential of breast cancer cells by increasing levels of microRNA-200c, which in turn suppressed epithelial--mesenchymal transition, a process that has been implicated as a key step in the development of metastatic disease. Therefore, GLA\'s ability to impair epithelial--mesenchymal transition is an exciting finding that may provide a new opportunity to treat breast cancer.
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